Alembic Pharmaceuticals Ltd - ALEMBIC PHARMA Share Price

Sector: Pharmaceuticals | ISIN: INE901L01018
₹ 1,048.35 (-2.89%) icon23 Feb, 2024, 12:00:00 AM

Alembic Pharmaceuticals Ltd Stock View

info icon
Edit Image
Target | 08 Feb, 2024 831 (-20.73%)

Alembic Pharmaceuticals Limited is an India-based pharmaceutical company. The Company is involved in manufacturing and marketing India Formulations, International Generics, and Active Pharma... Read More

Alembic Pharmaceuticals Ltd KEY RATIOS

sector: Pharmaceuticals

  • CMP

    as on 2/23/2024 12:00:00 AM

    ₹ 1048.35 -31.20 -2.89
  • Open
  • ₹ 1,085
  • Prev. Close
  • ₹ 1,079.55
  • Turnover(Lac.)
  • ₹ 1,526
  • Day's High
  • ₹ 1,085
  • Day's Low
  • ₹ 1,042.95
  • 52 Week's High
  • ₹ 1,094
  • 52 Week's Low
  • ₹ 462.3
  • Book Value
  • ₹ 248.21
  • Face Value
  • ₹ 2
  • Mkt Cap (₹ Cr.)
  • 20,606.7
  • P/E
  • 34.63
  • EPS
  • 30.28
  • Divi. Yield
  • 0.76

Alembic Pharmaceuticals Ltd Corporate Actions

18 Jan , 2024

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

18 Jan , 2024

12:00 AM

16 Oct , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

16 Oct , 2023

12:00 AM

05 Jun , 2023

12:00 AM

AGM

Announcement date: 05 Jun , 2023

View Details

21 Jul , 2023

12:00 AM

21 Jul , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

05 May , 2023

12:00 AM

Dividend

Dividend amount: 8
Announcement date: 05 May , 2023

View Details

24 Apr , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

02 Mar , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

Alembic Pharmaceuticals Ltd News and Update

Image not found
  • 23 February, 2024 |
  • 12:07 AM

Under the "ILS Hospitals" brand, GPT Healthcare Ltd. manages a network of mid-sized full-service hospitals that offer integrated healthcare services, with an emphasis on secondary and tertiary care.

Image not found
  • IIFL News Service |
  • 22 February, 2024 |
  • 12:06 AM
Image not found
  • IIFL News Service |
  • 22 February, 2024 |
  • 12:06 AM
Image not found
  • IIFL News Service |
  • 16 February, 2024 |
  • 11:57 PM

Invest wise with Expert advice

mobile icon
  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required

Alembic Pharmaceuticals Ltd SHAREHOLDING SNAPSHOT
26 February , 2024 | 02:37 AM

PROMOTER - TOTAL69.61%

Indian: 69.10%

Foreign: 0.5123%

NON-PROMOTER - TOTAL 30.39%

Institutions: 19.02%

Non-Institutions: 11.37%

CUSTODIES - 0.00%

Custodies: 0.00%

See More Details
ad IconAd Image

Alembic Pharmaceuticals Ltd FINANCIALS

Alembic Pharmaceuticals Ltd PEER COMPARISON

Figures of Market Capital(Mar Cap), Quaterly Net Profit(NP Qtr) and Quaterly Sales(Sales Qtr) are in ₹ Cr.View All Peer Comparison

MORE ABOUT Alembic Pharmaceuticals Ltd

  • Chirayu R Amin
  • Chairman & CEO
  • Pranav N Parikh
  • Independent Director
  • K G Ramanathan
  • Independent Director
  • Paresh Saraiya
  • Independent Director
  • Rajkumar Baheti
  • Director (Finance) & CFO
  • Pranav Amin
  • Managing Director
  • Shaunak Amin
  • Managing Director
  • Archana Hingorani
  • Independent Director
  • Ashok Barat
  • Independent Director
  • Manisha Saraf
  • Company Sec. & Compli. Officer
  • Jai S Diwanji
  • Independent Director

Summary

Alembic Pharmaceuticals manufactures and markets generic pharmaceutical products all over the world. The companys state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the US FDA. The company is one of the leaders in branded generics in India. Alembic Pharmaceuticals Ltd was incorporated on June 16, 2010 as a wholly owned subsidiary of Alembic Ltd. The company is engaged in pharmaceuticals business. As per the scheme of arrangement, the Pharmaceutical Undertaking of the Alembic Ltd was demerged and transferred to the company with effect from appointed date, April 1, 2010. In April 15, 2011, the company ceased to be a subsidiary of Alembic Ltd consequent to the allotment of 13,35,15,914 equity shares of Rs 2 each to the shareholders of Alembic Ltd as per the scheme of arrangement. The shareholding of Alembic Ltd in the company reduced from 100% to 29.18%. Thus, the company became an associate of Alembic Ltd.In September 20, 2011, the equity shares of the company were listed on the Bombay Stock Exchange and National Stock Exchange. During 2012, Alembic and Breckenridge Announced Paragraph IV ANDA Litigation with Pfizer on Desvenlafaxine (Pristiq). The company enters into a product development and license agreement with Accu-Break Pharmaceuticals, Inc, USA. During 2013, the company got USFDA approval for its NDA - Desvenlafaxine Base Extended Release Tablets and also entered into an out-licensing... Read More


Reports by Alembic Pharmaceuticals Ltd


Reports by Alembic Pharmaceuticals Ltd

Company FAQ

No Record Found